États-Unis · Actualité · The Hill

FDA: Mifepristone review won’t be done until March

Publié par The Hill · États-Unis il y a 2 h

The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it…

Lire l'article complet sur The Hill Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (thehill.com)

FDA: Mifepristone review won’t be done until March

À lire aussi

Trent Grisham can’t provide leadoff spark for Yankees with uncertainty looming

Nobel Prize in chemistry set to be awarded in Stockholm

Newly obtained footage shows Iran attack on major U.S. post in Kuwait

Trump says he won't let Iran strike L.A. or San Diego: 'Not going to let that happen'

Europe’s Trade Tensions With China Are Coming to a Head

Student loan borrowers have more time to reduce interest rates. Here's what to know

FDA: Mifepristone review won’t be done until March

Partager

À lire aussi

Trent Grisham can’t provide leadoff spark for Yankees with uncertainty looming

Nobel Prize in chemistry set to be awarded in Stockholm

Newly obtained footage shows Iran attack on major U.S. post in Kuwait

Trump says he won't let Iran strike L.A. or San Diego: 'Not going to let that happen'

Europe’s Trade Tensions With China Are Coming to a Head

Student loan borrowers have more time to reduce interest rates. Here's what to know